HOME >> MEDICINE >> NEWS
AMPAKINE compounds a new potential treatment for respiratory depression

Drug-induced respiratory depression is a life-threatening condition caused by analgesic, hypnotic, and anesthesia medications. Although it is a leading cause of death from the overdose of some classes of abused drugs, respiratory depression also arises during normal, physician-supervised procedures such as surgical anesthesia, post-operative analgesia, and as a result of normal out-patient management of pain from cancer, accidents, or illnesses.

The majority of adverse events occurring with these drugs take place during the dose adjustment period, when two or more central nervous depressants are taken together, or when patients take prescribed drugs in ways not intended by their physician.

Although only 0.5%-1.2% of total adverse drug events caused by prescription medications are respiratory in nature, these serious side effects account for 25%-30% of drug-induced deaths. Opiates and barbiturates are the primary drugs classes responsible for these effects. Opiates include the standard pain-killing drugs morphine, fentanyl, and codeine, as well as related products vicodin, hydrocodone, and oxycontin. Barbituates comprise the sedative drugs amobarbital, aprobarbital, butabarbital, pentobarbital, and others. Sleeping disorders are another common predisposing factor for respiratory depression, in this case known as sleep apnea.

Currently, the only way to counter opiate-induced respiratory depression is to administer opiate receptor antagonists, drugs that block the effectiveness of opiate analgesia. While this approach may prevent a serious side effect or even death, it dramatically reduces the effectiveness of drugs administered for management of severe pain.

Researchers at the University of Alberta (Edmonton, AB) and Cortex Pharmaceuticals (Irvine, CA) believe that AMPAKINE drugs may provide protection from drug-induced respiratory depression, while simultaneously allowing the sedative or analgesic to continue working as it
'"/>

Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007


Page: 1 2 3 4 5

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
3. U of M researchers discover compounds to shrink tumors
4. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue
5. New compounds fight chronic symptoms of bowel disorders
6. New synthetic compounds appear to prevent brain cell death
7. Phenolic compounds may explain Mediterranean diet benefits
8. Vitamin D compounds show promise for prevention of prostate cancer
9. Hebrew University researcher develops compounds to control bacteria
10. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2019)... ... ... TIME For Kids (TFK) revealed the first-ever list of the ... destinations that are tailored to the interests of kids. The list identifies The Children’s ... list, TIME for Kids gathered nominations from its network of TFK Kid Reporters ...
(Date:12/5/2019)... ... December 05, 2019 , ... Abide, the #1 Christian meditation and sleep ... year using Bible-based bedtime stories. Listeners have recovered from bad dreams and night terrors, ... for Disease Control, one third of Americans suffer from poor sleep, which is linked ...
(Date:12/5/2019)... ... December 05, 2019 , ... It’s been an impactful year ... help people embrace, achieve, and maintain a healthy lifestyle to giving generously to ... our mission of impacting world health, so it’s gratifying to look back on ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... Extract®, provides protection from disruptions to cells and tissue and inflammation that leads ... Jet Lag, is available in a dietary supplement product called Prepair™ . ...
(Date:12/4/2019)... ... 2019 , ... While the holidays are a time for joy and sharing, ... AgriLife Extension Service specialists. , “There are many behavioral and logistical ... wellness,” said Joyce Cavanagh, AgriLife Extension specialist in family economics, College Station. , Prioritize ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... ... December 05, 2019 , ... nView, a leading behavioral ... the role of Chief Product Officer. As the company expands its portfolio of ... the behavioral health market into nView’s product and company growth strategy. Rosenbaum will ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
(Date:12/4/2019)... ... December 04, 2019 , ... HGE Health, ... COPD patient’s symptoms, joined forces nearly a year ago with RespirCare, an operator ... care at times when the attention is most needed. The patient-satisfaction scores ...
Breaking Medicine Technology:
Cached News: